[go: up one dir, main page]

NO20064226L - mRNA-profering i spytt, biomarkorer og beslektede fremgangsmater og sett av deler - Google Patents

mRNA-profering i spytt, biomarkorer og beslektede fremgangsmater og sett av deler

Info

Publication number
NO20064226L
NO20064226L NO20064226A NO20064226A NO20064226L NO 20064226 L NO20064226 L NO 20064226L NO 20064226 A NO20064226 A NO 20064226A NO 20064226 A NO20064226 A NO 20064226A NO 20064226 L NO20064226 L NO 20064226L
Authority
NO
Norway
Prior art keywords
saliva
cell
mrna
detecting
biomarkers
Prior art date
Application number
NO20064226A
Other languages
English (en)
Other versions
NO340089B1 (no
Inventor
David T W Wong
Maie A R Stjohns
Yang Li
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO20064226L publication Critical patent/NO20064226L/no
Publication of NO340089B1 publication Critical patent/NO340089B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

En fremgangsmåte for å påvise en biomarkør i spytt der biomarkøren er et ekstracellulært RNA, som omfatter å påvise det ekstracellulære mRNA i det cellefrie spyttet, transkriptomanalyse av spytt omfatter å påvise et transkriptommønster i det cellefrie spyttet, en fremgangsmåte for å påvise genetiske endringer i et organ eller i et gen i organet ved å analysere spyttet, som omfatter å påvise et transkriptommønster og/eller mRNA-profileringen av genet i cellefritt spytt, en fremgangsmåte for å diagnostisere en oral eller systemisk patologi, sykdom eller forstyrrelse hos individet, som omfatter å: påvise en profil for en biomarkør som er assosiert med patologien, sykdommen eller forstyrrelsen, spesielt mRNA og/eller protein, i cellefritt spytt og/eller serum, sett som omfatter identifikator for minst én biomarkør for å utføre minst én av fremgangsmåtene og anvendelse av spyttbiomarkører og/eller serum-mRNA som biomarkører for oral og/eller systemisk patologi, sykdom eller forstyrrelse.
NO20064226A 2004-02-20 2006-09-19 Fremgangsmåte for å diagnostisere et orofaryngealt plateepitelkarsinom (OSCC) hos et individ ved påvisning av en biomarkør valgt fra gruppen som består av IL8, IL1B, DUSPl, H3F3A, OAZ1, S100P og SAT i cellefritt spytt NO340089B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54650704P 2004-02-20 2004-02-20
US54652104P 2004-02-21 2004-02-21
PCT/US2005/005263 WO2005081867A2 (en) 2004-02-20 2005-02-17 Salivary mrna profiling, biomarkers, and related methods and kits of parts

Publications (2)

Publication Number Publication Date
NO20064226L true NO20064226L (no) 2006-11-16
NO340089B1 NO340089B1 (no) 2017-03-06

Family

ID=34915575

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064226A NO340089B1 (no) 2004-02-20 2006-09-19 Fremgangsmåte for å diagnostisere et orofaryngealt plateepitelkarsinom (OSCC) hos et individ ved påvisning av en biomarkør valgt fra gruppen som består av IL8, IL1B, DUSPl, H3F3A, OAZ1, S100P og SAT i cellefritt spytt

Country Status (10)

Country Link
US (3) US10072297B2 (no)
EP (1) EP1730304B1 (no)
JP (2) JP4880484B2 (no)
KR (2) KR20070004725A (no)
CN (1) CN1977051B (no)
AU (1) AU2005216095B2 (no)
CA (1) CA2558666C (no)
IL (1) IL177579A (no)
NO (1) NO340089B1 (no)
WO (1) WO2005081867A2 (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005081867A2 (en) * 2004-02-20 2005-09-09 The Regents Of The University Of C Alifornia Salivary mrna profiling, biomarkers, and related methods and kits of parts
US7727715B2 (en) 2004-03-30 2010-06-01 Vector Tobacco, Inc. Global gene expression analysis of human bronchial epithelial cells exposed to cigarette smoke, smoke condensates, or components thereof
CA2574706A1 (en) * 2004-07-21 2006-02-23 The Regents Of The University Of California Salivary transcriptome diagnostics
WO2008001357A2 (en) * 2006-06-26 2008-01-03 Technion Research & Development Foundation Ltd. Methods and kits for diagnosing cancer
EP2083087B1 (en) * 2006-10-12 2013-05-15 Niigata University Method for determining tongue cancer
JP2008295327A (ja) * 2007-05-30 2008-12-11 Fujifilm Corp 口腔扁平上皮癌の検出方法、及び抑制方法
WO2008157501A1 (en) * 2007-06-15 2008-12-24 The Regents Of The University Of California Salivary exon core transcriptome
US20090053732A1 (en) 2007-07-16 2009-02-26 Ophir Vermesh Microfluidic devices, methods and systems for detecting target molecules
WO2010011860A1 (en) * 2008-07-23 2010-01-28 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes
CA2733246C (en) 2008-08-04 2018-02-20 Institut Clinident Method of evaluating oral cancer risk in human
US20130143747A1 (en) * 2011-12-05 2013-06-06 Myriad Genetics, Incorporated Methods of detecting cancer
US9075060B2 (en) 2009-06-16 2015-07-07 Technion Research & Development Foundation Limited Methods for diagnosing oral or oral-pharyngeal cancer
WO2010151789A1 (en) * 2009-06-25 2010-12-29 The Regents Of The University Of California Salivary transcriptomic and microbial biomarkers for pancreatic cancer
EP3461912B1 (en) 2009-09-09 2022-07-13 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
EP2475989A4 (en) 2009-09-09 2013-02-27 Gen Hospital Corp USE OF MICROVESICLES IN THE ANALYSIS OF KRAS MUTATIONS
JP2011072229A (ja) * 2009-09-29 2011-04-14 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた下咽頭がんの診断・治療選択
US8309299B2 (en) * 2010-05-19 2012-11-13 Hoffmann-La Roche Inc. Combination therapy and method for assessing resistance to treatment
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2638057B1 (en) 2010-11-10 2019-03-06 Exosome Diagnostics, Inc. Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
AU2012314514B2 (en) 2011-09-26 2018-03-15 Qiagen Gmbh Stabilisation and isolation of extracellular nucleic acids
ES2574956T3 (es) * 2011-09-26 2016-06-23 Preanalytix Gmbh Estabilización y aislamiento de ácidos nucleicos extracelulares
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
JP6197039B2 (ja) 2012-08-24 2017-09-13 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ ハイスループット多重検出用システム、装置及び方法
CA2884915C (en) 2012-09-25 2022-05-17 Qiagen Gmbh Stabilisation of biological samples
US20140188442A1 (en) * 2012-12-27 2014-07-03 Pearson Education, Inc. System and Method for Selecting Predictors for a Student Risk Model
WO2014146780A1 (en) 2013-03-18 2014-09-25 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
EP3447141B1 (en) 2013-03-18 2020-08-05 PreAnalytiX GmbH Stabilisation of biological samples
WO2014182598A1 (en) * 2013-05-06 2014-11-13 Physicians Choice Laboratory Services, Llc Diagnostic assay combining cellular and cell free nucleic acid
EP3064940B1 (en) * 2013-10-28 2019-07-03 Salivatech Co., Ltd. Salivary biomarker for pancreatic cancer
US20210005324A1 (en) * 2018-08-08 2021-01-07 Hc1.Com Inc. Methods and systems for a health monitoring command center and workforce advisor
US12027243B2 (en) 2017-02-17 2024-07-02 Hc1 Insights, Inc. System and method for determining healthcare relationships
GB201417281D0 (en) * 2014-09-30 2014-11-12 Ge Healthcare Uk Ltd Methods and devices relating to the detection of oral cancer biomarkers
WO2016090148A1 (en) 2014-12-03 2016-06-09 IsoPlexis Corporation Analysis and screening of cell secretion profiles
CN114965989A (zh) * 2015-02-09 2022-08-30 Dna吉诺特克股份有限公司 用于采集相关应用、分析和诊断的样本的设备、溶液和方法
US11353448B2 (en) 2015-02-13 2022-06-07 California Institute Of Technology Methods and compositions for quantifying metabolites and proteins from single cells
DK3262190T3 (da) * 2015-02-24 2021-10-11 Univ Heidelberg Ruprecht Karls Biomarkørpanel til påvisning af cancer
CA2989199A1 (en) 2015-07-01 2017-01-05 Duke University Methods to diagnose and treat acute respiratory infections
CN106446599A (zh) * 2015-08-11 2017-02-22 中国科学院青岛生物能源与过程研究所 一种筛选婴幼儿龋病的口腔致病性生物标记物的方法
CA3005694A1 (en) 2015-11-20 2017-05-26 Qiagen Gmbh Method of preparing sterilized compositions for stabilization of extracellular nucleic acids
GB201602210D0 (en) 2016-02-08 2016-03-23 Ucl Business Plc Detection of cancer
WO2018049418A1 (en) 2016-09-12 2018-03-15 IsoPlexis Corporation System and methods for multiplexed analysis of cellular and other immunotherapeutics
EP4036578A1 (en) 2016-11-11 2022-08-03 Isoplexis Corporation Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells
CN110226084A (zh) 2016-11-22 2019-09-10 伊索普莱克西斯公司 用于细胞捕获的系统、装置和方法，以及其制造方法
WO2018217849A1 (en) * 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Targeting of anaplastic lymphoma kinase in squamous cell carcinoma
WO2019084351A1 (en) * 2017-10-27 2019-05-02 The Regents Of The University Of California SALIVARY EXTRACELLULAR RNA BIOMARKERS FOR GINGIVITIS
US20210018507A1 (en) * 2018-03-04 2021-01-21 Mazumdar Shaw Medical Foundation Sall.ivary protein biomarkers for the diagnosis and prognosis of head and neck cancers, and precancers
EP3671213A1 (en) * 2018-12-20 2020-06-24 Kromat Muszerforgalmazó Kft. In vitro method for the diagnosis of malignant conditions
WO2020128546A1 (en) * 2018-12-20 2020-06-25 Kromat Műszerforgalmazó Kft. A simple, non-invasive method for diagnosing oral cancer
JP2020195314A (ja) * 2019-05-31 2020-12-10 医薬資源研究所株式会社 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体
JP7373843B2 (ja) * 2019-12-19 2023-11-06 国立大学法人東海国立大学機構 感染の原因生物を予測するための予測装置、予測プログラム及び予測方法
CN113985033B (zh) * 2021-10-19 2025-02-14 中山大学附属第八医院（深圳福田） 一种用于诊断骨质疏松症发生肌少症的生物标记物及检测试剂盒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511805B1 (en) 1996-03-15 2003-01-28 The Penn State Research Foundation Methods for detecting papillomavirus DNA in blood plasma and serum
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
US6759217B2 (en) 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US20020102553A1 (en) 1997-10-24 2002-08-01 University Of Rochester Molecular markers for the diagnosis of alzheimer's disease
US6294349B1 (en) * 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US6617112B2 (en) 2000-10-11 2003-09-09 Monsanto Technology Llc Methods for gene array analysis of nuclear runoff transcripts
ES2367280T3 (es) 2001-07-25 2011-11-02 Oncomedx Inc. Métodos para evaluar estados patológicos usando arn extracelular.
WO2005081867A2 (en) * 2004-02-20 2005-09-09 The Regents Of The University Of C Alifornia Salivary mrna profiling, biomarkers, and related methods and kits of parts

Also Published As

Publication number Publication date
JP2011229532A (ja) 2011-11-17
AU2005216095A1 (en) 2005-09-09
US20190040471A1 (en) 2019-02-07
CN1977051A (zh) 2007-06-06
HK1095163A1 (en) 2007-04-27
CN1977051B (zh) 2013-07-17
AU2005216095B2 (en) 2009-09-17
US9983210B2 (en) 2018-05-29
EP1730304A2 (en) 2006-12-13
CA2558666C (en) 2015-11-24
JP5367760B2 (ja) 2013-12-11
JP2007522819A (ja) 2007-08-16
EP1730304B1 (en) 2013-01-02
JP4880484B2 (ja) 2012-02-22
WO2005081867A3 (en) 2006-07-06
WO2005081867A2 (en) 2005-09-09
US10072297B2 (en) 2018-09-11
EP1730304A4 (en) 2007-10-24
CA2558666A1 (en) 2005-09-09
IL177579A (en) 2012-03-29
IL177579A0 (en) 2006-12-10
US20080280772A1 (en) 2008-11-13
NO340089B1 (no) 2017-03-06
KR20070004725A (ko) 2007-01-09
US20140249236A1 (en) 2014-09-04
KR20130018438A (ko) 2013-02-22

Similar Documents

Publication Publication Date Title
NO20064226L (no) mRNA-profering i spytt, biomarkorer og beslektede fremgangsmater og sett av deler
Radzikowska et al. Omics technologies in allergy and asthma research: an EAACI position paper
WO2010019550A3 (en) Method of identifying disease risk factors
NO20083461L (no) Genekspresjonsmarkorer for kolorektal cancer-prognose
WO2007038754A3 (en) Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
PT2185937E (pt) Método para ensaiar septicemia em seres humanos
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
MX2007014815A (es) Metodos de inmunoanalisis mejorados.
WO2009006323A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
WO2010061283A3 (en) Biomarkers for diagnosing and detecting the progression of neurodegenerative disorders, in particular of amyotrophic lateral sclerosis
JP2011503547A5 (no)
ATE373239T1 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
JP2015505370A5 (no)
WO2007025044A8 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
Eissa et al. Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease
EA201291228A1 (ru) Биомаркер для детекции высокогорной адаптации и высокогорного отека легких
MX2012014284A (es) Metodos y kits para diagnosticar afecciones relacionadas con hipoxia.
WO2005094332A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
ATE508364T1 (de) Diagnoseverfahren für präeklampsie
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
Addissouky et al. Emerging biomarkers for precision diagnosis and personalized treatment of cystic fibrosis
KR20250005003A (ko) 아토피성 피부염 진단용 바이오마커 및 이의 용도
WO2006092729A3 (en) Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals
WO2007133496A3 (en) Development of a novel assay for mgmt (methyl guanine transferase)
WO2006102526A3 (en) Identification of biomarkers by serum protein profiling

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees